Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research Report) yesterday and set a ...

According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, ...

The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed ...

Sedgwick brand protection has launched the first Australian edition of its Recall Index, which tracks product recalls and regulatory developments across five major industries.

( MENAFN - Jordan Times) AMMAN - The Jordan Chamber of industry said that the industry index, recorded a growth of 1 per cent ...

The sector is expected to benefit from steady cash flows and low financial leverage, which will help maintain stable credit ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.